Bevacizumab 5 or 7.5 mg/kg in metastatic colorectal cancer can be infused safely over 10 minutes

Journal of Gastrointestinal Cancer

Volumn 43, Issue 2, 2012, Pages 244-248

  Mahfoud, Tarik ^a,b   Tanz, Rachid ^a   Mesmoudi, Mohamed ^b   Khmamouche, Mohamed Réda ^a   Bazine, Aziz ^a   Aassab, Rachid ^b   Ismaili, Nabil ^b   Boutayeb, Saber ^b   Ichou, Mohamed ^a   Errihani, Hassan ^b  

^a MILITARY HOSPITAL MOHAMMED V   (Morocco)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

Author keywords

10 min; Bevacizumab; Infusion

Indexed keywords

BEVACIZUMAB; CAPECITABINE PLUS OXALIPLATIN; HYDROXYZINE; METHYLPREDNISOLONE;

ADULT; ARTICLE; BLOOD PRESSURE; CANCER CHEMOTHERAPY; COLORECTAL CANCER; COUGHING; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FEMALE; FLUSHING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; WHEEZING;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES;

EID: 84863874051     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-010-9245-x     Document Type: Article

References (22)

1. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999;59:5209-18. (Pubitemid 29503984)
2. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841-4. (Pubitemid 23132159)
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42. (Pubitemid 38702844)
4. Giantonio BJ, Catalano PJ, Meropol NJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. ASCO Annual Meeting. Abstract no: 2, 2005.
5. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006;355:2542-50. (Pubitemid 44917502)
6. Reck M, Von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol. 2009;27:1227-34.
7. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-76.
8. Miles D, Chan D, Romieu G et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. ASCO Annual Meeting. Abstract No 1011, 2008
9. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). ASCO Annual Meeting. Abstract No 1005, 2009.
10. Escudier B, Pluzanska A, Koralewski P, et al. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet. 2007;370:2103-11. (Pubitemid 350296300)
11. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone or in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;25:4733-40.
12. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740-5.
13. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697-705.
14. Giantonio BJ, Catalano PF, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-44. (Pubitemid 46733080)
15. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-9.
16. Reidy DL, Chung KY, Timoney JP, et al. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol. 2007;25:2691-5. (Pubitemid 47123175)
17. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-81. (Pubitemid 36962641)
18. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-5.
19. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792-9. (Pubitemid 46224178)
20. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117-26. (Pubitemid 46211317)
21. Foran JM, Cunningham D, Coiffier B, et al. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol. 2000;11:117-21.
22. Hallek M, Fingerle-Rowson G, Fink AM. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). ASH. Abstract No 325, 2008.